Home > About Us
We're with you.
Longer than any other manufacturer, Shire* has been a reliable and consistent supplier of Ig treatment.1
Through Growth and Transition
Shire's* investments in plasma treatment processing have grown from $614 million to $1.2 billion in recent years, and Shire is committed to continued investment in the future.1
With 60 state-of-the-art plasma collection centers, Shire collects nearly 4 million liters of source plasma each year to meet the needs of those who rely on plasma-based treatment.2,3 Shire also has the largest fractionation capacity among all plasma manufacturers and plans to build a new facility that will add up to 3 million liters of fractionation capacity annually when fully functional.1
With Education and Support
Shire offers unprecedented support and a wealth of educational resources, created with the help of patients, caregivers, and healthcare professionals from the community. Support is offered without charge to patients and caregivers, regardless of treatment.
Learn more about MyIgSource.
Yesterday, Today, and Tomorrow
Shire plc* became a leader in plasma fractionation in 1941 and is the only company that has been continuously processing IVIG for 25 years.4 Our aim is to provide the highest quality products and programs that advance patient care globally and enable the achievement of outcomes through innovation, science, and technology.
*Shire plc bought Baxalta Incorporated in 2016. Baxalta Incorporated was formerly the BioScience Division at Baxter International Inc. and continues to provide those same treatments and products.
References: 1. Baxter International Inc. 2012 Annual Report. 2. BioLife Press Kit. //biolifeplasma.com/downloads/biolife-press-kit.pdf. Accessed June 24, 2013. 3. Data on file (BioLife Directory). Baxter Healthcare Corporation. 4. Marketing Research Bureau. The plasma proteins market in the United States 2011. Published June 2012.